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Abstract
Background: Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This
study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among
middle-aged and older adults.
Methods: Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were
prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal
or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association
between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying
risk conditions.
Results: Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13
vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7–88.1)
for pneumococcal pneumonia, 637.9 (95% CI: 599.0–678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8–2518.7)
for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the
risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75–1.83; p = 0.493) and all-
cause death (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190), although it remained significantly associated with an increased
risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48–1.94; p < 0.001). In stratified analyses focused on middle-aged or
elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective
either.
Conclusion: Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in
Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.
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Background
Pneumococcal infections are a major cause of morbidity
and mortality, especially among infants, high-risk adults
and elderly people [1]. Among adults, apart from the
classical 23-valent pneumococcal polysaccharide vaccine
(PPsV23), [2] a 13-valent protein-polysaccharide conju-
gate vaccine (PCV13) has been available for use in adults
since 2012 [3].
At present, the Advisory Committee on Immunization
Practices (ACIP) of the Centers for Disease Control and
Prevention (CDC, Atlanta, Ga, USA) recommends
PCV13 vaccination (sequentially with the PPsV23) for
those persons aged 19–64 years who have high-risk con-
ditions (mainly anatomical or functional asplenia and
immunocompromising conditions) and all persons
65 years or older (with or without risk conditions) [4, 5].
These recommendations are based on immunogenicity
studies (which showed that PCV13 induced an immune
response as good as or better than that induced by
PPsV23 for common serotypes) [6, 7] and the results of
the CAPITA study (a randomised-controlled trial [RCT]
comparing PCV13 vs placebo among elderly individuals
in the Netherlands) [8] which reported a PCV13 efficacy
of 46% against vaccine-type invasive pneumococcal in-
fections. However, some experts and clinicians are not in
accordance with a positive interpretation of data re-
ported in the CAPITA trial and disagree with ACIP’S
recommendations [9–11].
In Catalonia, a region in Northeastern Spain with ap-
proximately seven million people, the PPsV23 has been
recommended for high-risk and older adults since the
2000s, reaching a coverage of approximately 60–70% in
these persons [12]. The PCV7/PCV13 have been used
for childhood immunisation since they were marketed in
2001 and 2010, respectively, reaching intermediate vac-
cination coverage (48% in at-risk infants) [13]. Among
adults, the PCV13 is recommended and publicly funded
for some high-risk individuals (basically immunocom-
promised patients), [14] being also prescribed by some
clinicians for adults with other risk conditions (chronic
pulmonary or respiratory disease, heart disease, liver dis-
ease, diabetes mellitus, etc) although it is not publicly
funded in these patients and, consequently, PCV13
coverage remains low [12].
Considering this, we designed a population-based co-
hort study, known as EPIVAC (Effectiveness of Pneumo-
coccal and Influenza Vaccinations among Adults in
Catalonia), with the major aim of evaluating possible
clinical benefits of antipneumococcal and influenza vac-
cinations among the general population over 50 years. In
this report we have analysed the clinical effectiveness of
PCV13 vaccination in preventing hospitalisation for
pneumonia (pneumococcal and all-cause) in the study
cohort at one-year follow-up. In addition, considering
the debate about current PCV13 recommendations, we
have also assessed vaccination effectiveness in stratified
analyses according to age subgroups and immunological
situation.
Methods
Design, setting and study population
This is a closed population-based prospective cohort
study involving 2,025,730 middle-aged and older adults
in Catalonia, Spain. Cohort members were all persons
assigned to the 274 Primary Health Care Centres
(PHCCs) managed by the Catalonian Health Institute
(Institut Catala de la Salut, ICS) who were aged 50 years
or older at December 31, 2014.
In the study setting, similar to the rest of Spain, all
inhabitants are covered by the National Health Service
by a compulsory health assurance system; so, all inhabi-
tants are assigned to a PHCC. Around Catalonia there
are 358 PHCCs, of which 274 (76.5%) are managed by
the ICS and 84 PHCCs are managed by other providers.
The analysed cohort (n = 2,025,730 persons) represents a
75.2% of the total 2,693,570 Catalonian inhabitants over
50 years-old according to 2014 census data (Fig. 1).
Cohort members were followed since the beginning of
the study (01/01/2015) until the occurrence of any event,
disenrollment from the PHCC, death, or until the end of
one-year follow-up (31/12/2015).
The study was approved by the ethical committee of
the Institution (ethic committee IDIAP Jordi Gol, file
P14/134) and was conducted in accordance with the
general principles for observational studies [15].
Data sources
The Information system for the development of research
in primary care of Catalonia (SIDIAP), [16] which com-
piles administrative data and clinical information con-
tained in the Electronic PHCC’s medical records, was
used to identify vaccinations, comorbidities and under-
lying risk conditions among study subjects and to estab-
lish baseline characteristics of cohort members at study
start. We assumed that information in primary care clin-
ical records was complete; so, a vaccination, comor-
bidity or risk condition was considered absent if it
was not recorded. Quality criteria for clinical data of
the SIDIAP research database has been reported else-
where [17].
To identify study events (hospitalisations for pneumo-
coccal and all-cause pneumonia) occurred among cohort
members across study period, we used the national sur-
veillance system for hospital discharge data (“Conjunto
Minimo Basico de Datos”, CMBD) maintained by the
Spanish Ministry of Health [18]. The CMBD system in-
cludes 98% of Spanish hospitals, covering an estimated
99.5% of the Spanish population (covered in the National
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Health Care System by a compulsory health insurance).
In the present study we used CMBD hospital discharge
codes, coded according to the International Classifica-
tion of Diseases, 9th Revision, Clinical Modification
(ICD-9), reported during 2015 from the 68 Catalonian
hospitals.
Data set linkage
The two data sets (SIDIAP and CMBD) were linked by
the Catalan Institute of Health (ICS), the public health
provider, that acts as the trusted third part between
SIDIAP and CatSalut (the Catalan Service of Health,
whose have the hospital admissions).
The steps to made the linkage were as follows:
 SIDIAP provides the anonymous identifies of the
cohort of the project to the ICS.
 The ICS translates the identify to the CIP, the
Patient Identification Code, that is the unique
identifier of a patient in Catalonia.
 Catsalut returns the hospital data related to those
patients to the ICS.
 The ICS anonymizes back the IDs and get the data
back to SIDIAP, this time including the hospital
data.
The Catalan Institute of Health is the only that can
made the linkage because they know the relation
between the anonymous identifier and the open one
(the CIP).
Fig. 1 Number of individuals at each stage of the study, vaccination status and endpoints across one-year follow-up
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As the assignation of patients is done through the CIP,
it is directly, is not a probabilistic assignation; so, there
are not duplications. The only possible case is which one
patient does not link with any CIP, and in this situation
it will not have hospital admissions.
Outcome definitions
Pneumococcal pneumonia (ICD-9: 481) and all-cause
pneumonia (ICD-9: 480 to 487.0) were defined on the
basis of hospital discharge codes (any diagnostic pos-
ition) reported by the CMBD in hospitalisations oc-
curred among cohort members from 01/01/2015
throughout 31/12/2015. Only a first episode of hospital-
isation from pneumonia during the study period was
considered; so, the analyses do not include multiple
events per person. Death from any cause was considered
according to administrative data (vital status), which is
periodically updated in the SIDIAP data base. Death
from pneumonia (case-fatality) was considered when the
patient died (in-hospital or not) within the first 30-day
after pneumonia diagnosis.
Because of the enormous size of the study cohort, an
active following of study participants was considered not
feasible. Nevertheless, all participating hospitals in the
study setting basically apply similar diagnostic checklist
and treatment for patients presenting with a clinical sus-
picion of pneumonia (which is established on the basis
of an acute respiratory illness, with evidence of the pres-
ence of a new infiltrate in a chest radiograph). Conven-
tional diagnostic workup included blood culture, sputum
culture and S. Pneumoniae urinary antigen test (Binax-
NOW), which were performed as indicated by the at-
tending physician in each case.
Exposure
The main explanatory variable was PCV13 vaccination
status. It was determined by a review of the PHCCs’
electronic clinical records which contain specially desig-
nated fields for pneumococcal and influenza vaccina-
tions (virtually all of them are administered at the
PHCCs in the Spanish Health System). At the beginning
of the study, cohort members were classified into the
PCV13 vaccinated group if they had received at least
one dose of PCV13 before the study started. Across the
study period, PCV13 vaccination status was a time-
varying condition given some individuals received the
vaccine after the study start. Subjects were considered to
be vaccinated 14 days after vaccine administration. For
the PPsV23 vaccination status as covariate, cohort mem-
bers were considered vaccinated if they had received the
vaccine at any time. For influenza vaccination status, co-
hort members were considered as vaccinated if they had
received the flu vaccine in the prior autumn.
Covariates
Besides PPsV23 and influenza vaccine status, baseline
covariates were age, sex, history of hospitalisation for
pneumococcal disease or pneumonia during the previous
24-month, presence of chronic pulmonary/respiratory
disease, chronic heart disease, diabetes mellitus, chronic
liver disease, alcoholism, current smoking, and immuno-
logical situation. Immunocompromise was a composite
variable defined by the presence of any one of the fol-
lowing: immunodeficiency/HIV infection, asplenia,
chronic renal disease, bone marrow transplantation, can-
cer and/or immunosuppressive medication. Definitions
used to identify comorbidities/underlying conditions are
listed in the Appendix.
Statistical analysis
Incidence rates were calculated as person-years, consid-
ering in the denominator the sum of the persons-time
contributed to each individual during the study period.
Baseline characteristics according to PCV13 vaccination
status were compared using Chi-squared or T test as
appropriate.
Cox regression models for time-varying covariables
were used to evaluate the association between having re-
ceived the PCV13 and the time of the first outcome dur-
ing the study period [19]. Pneumococcal vaccination
status was a time-varying condition, whereas the other
covariates were defined at study entry. All abovemen-
tioned covariates were initially considered potential can-
didates for the calculation of multivariable Cox models.
The method to select a subset of covariates to include in
the final models was the purposeful selection [19]. The
proportional hazard assumptions were assessed by add-
ing the covariate by log-time interactions to the model.
PPsV23 and influenza vaccine status were judged epide-
miologically relevant covariates, being included in all the
final models. All models were compared by the partial
likelihood ratio test and Akaike information criterion.
Besides the main analysis including all study popula-
tion, we performed four supplementary stratified ana-
lyses focused on middle-age individuals (50–64 years),
elderly people (65 years or older), immunocompetent
and immunocompromised persons.
All results were expressed with 95% confidence inter-
vals (CIs). Statistical significance was set at p < 0.05
(two-tailed). The analyses were performed using Stata/
SE 12.1 (Stata Corp.).
Rationale for sample size and statistical power: with
an expected incidence of 7 cases per 1000 persons-
year for all-cause pneumonia, considering a PCV13
coverage of 0.5%, with a p = 0.05 (two-tailed) the
study cohort (N = 2,025,730 individuals followed dur-
ing a one-year period) has a statistical power of 70%
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to detect a possible PCV13 effectiveness of 35%
against this outcome.
Results
The 2,025,730 cohort members were observed for a total
of 1,990,701 person-years, of which 6912 person-years
were PCV13 vaccinated. At study start, 5010 cohort
members had received PCV13. Of the remaining
2,020,720 cohort members initially classified into the
non-vaccinated group, 4460 received PCV13 later (con-
tributing to the analyses with 2260 person-years in the
non-vaccinated group and 2153 person-years in the vac-
cinated group).
At baseline, mean age of participants was 66 years-old
(SD: 11.5) and 932,072 (46%) were male. PCV13 vacci-
nated subjects were older, suffered more comorbidities,
and had a higher proportion of PPsV23 and influenza
vaccination than PCV13 unvaccinated subjects (Table 1).
During the study period, 47,265 (2.3%) cohort mem-
bers died and 14,488 (0.7%) moved or were lost patients.
An amount of 12,699 cohort members had a first
episode of hospitalisation for all-cause pneumonia, of
which 1648 were pneumococcal pneumonia (Fig. 1).
Incidence rates (per 100,000 person-years) were 82.8
(95% CI: 77.7–88.1) for pneumococcal pneumonia (289.3
in PCV13 vaccinated vs 82.1 in PCV13 unvaccinated),
637.9 (95% CI: 599.0–678.7) for all-cause pneumonia
(3298.6 in PCV13 vaccinated vs 626.6 in PCV13 unvaccin-
ated) and 2367.2 (95% CI: 2222.8–2518.7) for all-cause
death (5944.1 in PCV13 vaccinated vs 2354.5 in PCV13
unvaccinated).
Considering all-pneumonia cases, case-fatality was
8.3% (19/228) in PCV13 vaccinated vs 6.7% (836/12471)
in PCV13 unvaccinated (p = 0.330). Considering pneumo-
coccal pneumonia, case-fatality was 10% (2/20) in
PCV13 vaccinated vs 4.9% (79/1628) in PCV13 unvac-
cinated (p = 0.290).
Table 2 shows absolute number of events, incidences
and risks of hospitalisation for pneumococcal pneumo-
nia, all-cause pneumonia and all-cause death according
to PCV13 vaccination status in the total study popula-
tion. In the unadjusted analyses, as well as in the age









50-64 years 1,393 (27.8) 1,015,783 (50.3) <0.001
65-79 years 2,256 (45.0) 687,149 (34.0)
≥ 80 years 1,361 (27.2) 317,788 (15.7)
Sex, male 2,750 (54.9) 929,322 (46.0) <0.001
History of pneumococcal disease in previous 2 yrs. 91 (1.8) 2,634 (0.1) <0.001
History of all cause pneumonia in previous 2 yrs. 324 (6.5) 14,432 (0.7) <0.001
PPV23 vaccination at any time 4,050 (80.8) 782,896 (38.7) <0.001
Influenza vaccination in the prior autumn 4,143 (82.7) 679,345 (33.6) <0.001
Chronic respiratory disease 1,605 (32.0) 209,916 (10.4) <0.001
Chronic heart disease 1,553 (31.0) 245,929 (12.2) <0.001
Diabetes mellitus 1,574 (31.4) 338,749 (16.8) <0.001
Chronic liver disease 341 (6.8) 41,173 (2.0) <0.001
Chronic renal disease 454 (9.1) 16,302 (0.8) <0.001
Alcoholism 162 (3.2) 58,313 (2.9) 0.142
Smoking 465 (9.3) 315,613 (15.6) <0.001
Immunocompromisec 2,109 (42.1) 173,945 (8.6) <0.001
Multiple comorbidities
Immunocompetent subjects 920 (18.4) 220,718 (10.9) <0.001
Immunocompromised subjects 1,696 (33.9) 106,667 (5.3) <0.001
a p values were calculated with chi-square test.
b At the beginning of the study, mean age of the unvaccinated and vaccinated subjects were 66.02 years (Standard Deviation, SD: 11.46) and 71.47 years
(SD: 10.83) respectively.
c Immunocompromise was a composite variable defined by the presence of any one of the following: cancer (solid organ or haematological neoplasia), chronic
severe nephropathy (nephrotic syndrome, renal failure, dialysis or transplantation), anatomical or functional asplenia, immunodeficiency (including AIDS), and
long-term corticosteroid therapy (20 mg/day of prednisone) or another immunosuppressive medication.
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and sex-adjusted analyses, PCV13 was associated with
an increased risk for all analysed outcomes. In the multi-
variable analyses, PCV13 vaccination did not alter sig-
nificantly the risk of pneumococcal pneumonia
(multivariable Hazard Ratio [mHR]: 1.17; 95% CI: 0.75–
1.83; p = 0.493) or all-cause death (mHR: 1.07; 95% CI:
0.97–1.18; p = 0.190), but it remained significantly asso-
ciated with an increased risk of all-cause pneumonia
among vaccinated subjects (mHR: 1.69; 95% CI: 1.48–
1.94; p < 0.001).
In stratified analyses according to age subgroups and
immunological situation (Table 3), after multivariable
adjustments the PCV13 vaccination did not shown any
significant effect against pneumococcal pneumonia and
all-cause death. However, it appeared significantly asso-
ciated with an increased risk of all-cause pneumonia
among elderly people (mHR: 1.76; 95% CI: 1.52–2.04; p
< 0.001), immunocompromised persons (mHR: 1.51; 95%
CI: 1.24–1.83; p < 0.001) and immunocompetent subjects
(mHR: 1.86; 95% CI: 1.55–2.25; p < 0.001).
Discussion
Clinical benefits using PCV13 in adults are controversial
[8–11]. We undertook a large population-based cohort
study to investigate the clinical effectiveness of PCV13
vaccination in preventing hospitalisations for pneumo-
coccal and all-cause pneumonia among middle-aged and
older adults in Catalonia. To our knowledge, apart from
the CAPITA trial, [8] this is the first large prospective
study evaluating this issue in practice.
As main findings, PCV13 vaccination did not emerge
effective to prevent pneumonia and/or death in our
study population. In the initial unadjusted analyses,
crude incidence rates for all analysed outcomes were
largely greater in PCV13 vaccinated than in PCV13 un-
vaccinated subjects, reflecting the baseline excess risk of
Table 2 . Incidence and Risk of hospitalisation for pneumococcal pneumonia, all-cause pneumonia and death from any cause in
relation to PCV13 vaccination status in the total study population (N=2,025,730)
Event
Parameter
Pneumococcal pneumonia All cause pneumonia Death from any cause
Number of events
Vaccinated 20 228 420
Unvaccinated 1,628 12,471 46,845
Unadjusted incidence rate per 1000
person-years
Vaccinated 289.3 3,298.6 5,944.0
(95% CI) (176.8-445.5) (2,909.4-3,740.6) (5,385.2-6,562.1)
Unvaccinated 82.1




Unadjusted hazard ratio 3.70 5.44 2.51
(95% CI) (2.38-5.76) (4.77-6.20) (2.28-2.76)
p value <0.001 <0.001 <0.001
Age and sex adjusted hazard ratio 2.40 3.42 1.68
(95% CI) (1.55-3.74) (3.00-3.89) (1.53-1.85)
p value <0.001 <0.001 <0.001
Multivariable-adjusted hazard ratio 1.17a 1.69b 1.07c
(95% CI) (0.75-1.83) (1.48-1.94) (0.97-1.18)
p value 0.493 <0.001 0.190
NOTE: The hazard ratios are for PCV13 vaccinated subjects as compared with PCV13 unvaccinated subjects.
aadjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory
disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, immunodeficiency, HIV infection, chronic renal disease, cancer,
immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza vaccine in prior autumn.
b adjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory
disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, immunodeficiency, HIV infection, chronic renal disease, bone marrow
transplantation, cancer, immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza
vaccine in prior autumn.
cadjusted for age (continuous), sex, history of pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory
disease, chronic heart disease, diabetes, chronic liver disease, alcoholism, current smoking, asplenia, immunodeficiency, HIV infection, chronic renal disease, bone
marrow transplantation, cancer, immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of
influenza vaccine in prior autumn.
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vaccinated (who had higher prevalence of underlying
risk conditions than unvaccinated subjects). After multi-
variable adjustments we found that PCV13 vaccination
did not alter significantly the risk of hospitalisation for
pneumococcal pneumonia and/or all-cause death, but it
remained significantly associated with an increased risk
of hospitalisation for all-cause pneumonia (mHR: 1.69;
95% CI: 1.48–1.94) considering the total study cohort. In
stratified analyses focused on immunocompromised per-
sons and elderly individuals, main target groups where
PCV13 is currently recommended, [4, 5] the PCV13 did
not emerge effective either. In fact, excluding middle-
aged individuals, PCV13 vaccination appeared signifi-
cantly associated with an increased risk of all-cause
pneumonia in all analysed strata.
Although apparently opposite, our data does not fully
disagree with data reported in the CAPITA trial (the
unique RCT that has evaluated the clinical efficacy of
the PCV13 in adults to date) [8]. Concretely, the
CAPITA study (large RCT comparing PCV13 vs placebo
among 84,496 individuals ≥65 years in the Netherlands)
reported a significant PCV13 efficacy of 45.6% (95% CI:
21.8% to 62.5%) against vaccine-type pneumococcal pneu-
monia but did not show any significant efficacy of PCV13
against all-cause pneumonia, death from pneumonia and
all-cause death [8]. The reported PCV13 efficacy against
all-type pneumococcal pneumonia was 30.6% (95% CI:
9.8% to 46.7%) in the CAPITA trial, [8] which overlaps
with data observed in the present study (mHR: 1.17; 95%
CI: 0.75–1.83). On other hand, considering all-cause pneu-
monia, we note that a null or negative effect of PCV13
against all-cause community-acquired pneumonia was not
fully excluded among the general elderly population in the
CAPITA study (PCV13 efficacy: − 5%to 14%) [8].
We highlight that comparison is difficult due to im-
portant methodological and epidemiological differences
between both studies. Indeed, while no routine anti-
pneumococcal vaccination for adults and/or children
had been introduced in the Netherlands when the
CAPITA trial started, [20] the PPsV23 for adults and the
PCV7/PCV13 for children had been used in Catalonia
since the 2000s [12, 13]. Thus, the PCV13 efficacy esti-
mates in a population with an expected greater preva-
lence of circulating PCV13 serotypes can not be fully
compared with the PCV13 effectiveness in a population
with a minor prevalence of circulating PCV13-serotypes
(if a herd effect from PCV’s childhood immunisation
may be expected) [21].
At present, because the risk of immunization is be-
lieved to be very small, many experts and clinicians rec-
ommend pneumococcal vaccination for all persons with
an increased risk of infection or death (i.e, high-risk
Table 3 Stratified analyses on PCV13 effectiveness according to age subgroups and immunological situation











Number of events 350 1,298 401 1,247
Multivariable HR 0.58 1.32 0.86 1.47
(95% CI) (0.20-1.67) (0.81-2.18) (0.44-1.69) (0.81-2.68)
p value 0.314 0.268 0.664 0.204
All cause pneumonia
Number of events 2,115 10,584 3,222 9,477
Multivariable HR 1.21 1.76 1.51 1.86
(95% CI) (0.85-1.72) (1.52-2.04) (1.24-1.83) (1.55-2.25)
p value 0.283 <0.001 <0.001 <0.001
All cause death
Number of events 4,984 42,281 14,615 32,650
Multivariable HR 1.01 1.06 1.01 1.10
(95% CI) (0.77-1.32) (0.95-1.17) (0.88-1.14) (0.95-1.27)
p value 0.951 0.309 0.928 0.217
The HRs (hazard ratios) are for PCV13 vaccinated subjects as compared with PCV13 nonvaccinated and were adjusted, where appropriate, for age, sex, history of
pneumococcal disease or pneumonia during the previous 24 months, presence of chronic pulmonary/respiratory disease, chronic heart disease, diabetes, chronic
liver disease, alcoholism, current smoking, asplenia, immunodeficiency, HIV infection, chronic renal disease, bone marrow transplantation, cancer,
immunosuppressive therapy, history of pneumococcal polysaccharide vaccination at any time and receipt or non receipt of influenza vaccine in prior autumn
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adults and elderly persons) [4, 5, 22, 23]. However, we
note that having an increased risk of suffering a
pneumococcal infection (e.g. immunocompromising or
other risk conditions) does not necessarily imply that
vaccination of these persons will be an effective measure
in the practice [24–26]. According to our results, the
possibility of a harm effect of PCV13 vaccination (in-
creasing the risk of all-cause pneumonia) may not be
completely excluded. Hypothetically, since PCV13 vac-
cination may reduce pneumococcal carriage/colonization
and this could alter the nasopharyngeal/respiratory tract
flora, an increase in infections by other microorganisms
(especially in high-risk or elderly individuals) could be a
possible explanation for this unexpected finding.
The authors underline the importance of RCT data,
and note the limited amount of such data regarding clin-
ical efficacy of PCV13 in adults. Clinical outcomes of pa-
tients are affected by many factors, being antibody
production and associated phagocyte stimulation only
one aspect, which incompletely represent the immune
response overall (especially aging immune response) and
may not adequately reflect the potential impact of the
vaccine on clinical outcomes [2, 3, 27].
Major strengths in this study were the large size and
representativity of the study cohort (involving more than
2 million people, almost 80% of overall population over
50 years in Catalonia), and the use of survival analysis
methods to estimate PCV13 effectiveness against public
healt relevant outcomes such as hospitalisation from
pneumococcal or all-cause pneumonia and all-cause
death. Although it is not a RCT, the large size of the
study population together with the adjustment of major
possible confounding variables (e.g, history of previous
pneumococcal disease or pneumonia, comorbidities and
underlying risk conditions, PPsV23 and influenza vaccin-
ation status) in the multivariable analyses may provide
an acceptable basis to assess the potential effects of
PCV13 vaccination in adults at present.
Major limitations in this study are related with its ob-
servational nature: mainly, the non-randomised vaccin-
ation and the scarce PCV13 coverage in the study
population (which limits statistical power to evaluate
vaccination effectiveness against uncommon events, es-
pecially in subgroups analyses). The authors recognize
these inherent limitations but note that, opposite to
“vaccine efficacy” that must be evaluated by trials with
controlled conditions, “vaccination effectiveness” may be
evaluated by observational studies conducted in the real-
practice conditions (i.e., study populations where the
vaccine is not routinely used or it is more frequently
prescribed for persons with underlying risk conditions as
in the present study).
In this study, the large differences in outcomes be-
tween PCV13 vaccinated and unvaccinated suggest that
vaccinated persons were sicker. The large differences ob-
served in crude incidence rates between vaccinated and
unvaccinated mostly resolved in the multivariable ana-
lysis, although a residual confounding due to unobserved
factors (as all observational studies) may not be com-
pletely excluded [19]. In favour of a non important re-
sidual confounding in the final PCV13 effectiveness
estimates, we note that the adjusted risk of all-cause
death did not significantly differ between vaccinated and
unvaccinated (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190),
despite crude mortality had been more than double in
vaccinated (5944 per 100,000) than in unvaccinated
(2354 per 100,000).
Our study is not able to assess the possible overall ef-
fect of PCV13 against all pneumonia (including out-
patient cases) because only hospitalisations from
pneumonia were included. We note that pneumonia
cases managed outside the hospital could represent ap-
proximately a 25% of overall pneumonia cases in older
adults and this was not evaluated in the present study.
In the present study, comorbidities/underlying risk
conditions for pneumococcal disease were considered
only at baseline. Incident comorbidities occurred after
study start were not assessed, which could affect vac-
cination effectiveness estimates for the subgroup of
patients who developed later any of these comorbidi-
ties/risk conditions considered as an indication for
PCV13 vaccination. Basically, this could affect to
immunocompromising conditions (although their ex-
pected incidence would be small). We note that the
majority of comorbidities/risk conditions related to
PCV13 indication are prevalent conditions (mainly
chronic illnesses), which were established at baseline
and little incidence of new cases would be expected
throughout one-year period after study start.
On other hand, although the validity of clinical data
source was previously checked, [16] information bias
may have occurred if some vaccinations and/or co-
morbidities/underlying conditions were not recorded.
We do not have available data for pneumococcal se-
rotypes (which is not reflected in the Spanish CMBD
system) and, consequently, vaccination effectiveness
against vaccine-type pneumococcal infections (the
most specific outcome evaluating vaccine efficacy) can
not be assessed in the present study. We note, how-
ever, that the expected incidence of this outcome is
low (10.2 cases per 100,000 elderly population-year
according to laboratory-based epidemiological data in
Catalonia during 2014) [28] and underline the fact
that our study provides other very important data
from a clinical and public health point of view (such
as hospitalisation for pneumococcal and all-cause
pneumonia, death from pneumonia and death from
any cause).
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Conclusions
In the present population-based cohort study involving
more than 2 million people over 50 years old in Catalo-
nia, clinical benefits from PCV13 vaccination have not
emerged. Apart from a possible protective effect of the
PCV13 against vaccine-type infections (which can not be
assessed in the present study), our unadjusted and ad-
justed data show that PCV13 vaccination did not pro-
vide clinical benefits in reducing hospitalisation from
overall pneumococcal pneumonia, as in the general
people over 50 years old as well as in immunocomprom-
ised subjects and elderly individuals (main targeted
groups where PCV13 is currently recommended in
adults). Our data does not exclude a possible null or
negative effect (increasing risk of all-cause pneumonia)
among PCV13 vaccinated subjects, which should be
closely surveilled in future years.
We note that this study has been made in a single
geographical region, Catalonia, with intermediate/high
PCV13 and PPsV23 uptakes in children and older
adults, respectively, [12, 13] and moderate incidence
of pneumococcal infections [28]. Logically, PCV13
impact/effectiveness may vary in other geographical
settings depending on multiple factors (such as sus-
ceptibility for pneumococcal infections among the
population, prevalence of distinct circulating sero-
types, PPsV23 coverage, routine use of PCV13 in chil-
dren, possible herd effects, etc).
We emphasize that our findings must be interpreted
with caution because PCV13 coverage was low, vaccin-
ation was not randomised and time follow-up was lim-
ited. Further investigations involving more vaccinated
person-years at-observation are needed to confirm or
reject these early results.
Appendix
Criteria used to identify comorbidities and underlying risk
conditions in the study population.
The following comorbidities and underlying risk condi-
tions were established according to the presence of ICD-
10 codes [International Classification of Diseases, 10th
Revision] registered in the electronic primary medical
records of each cohort member at baseline:
 Chronic pulmonary/respiratory disease: it
included chronic bronchitis/emphysema (J41-J44),
asthma (J45-J46) and/or other chronic pulmonary
diseases (P27, E84, J47)
 Chronic heart disease: it included congestive heart
failure (I50), coronary artery disease (I20-I22, I25)
and/or other chronic heart diseases (I05-I08,
I11,I35-I37,I42, I51.7)
 Diabetes mellitus (E10-E14).
 Chronic liver disease: it included chronic viral
hepatitis (B18), cirrhosis (K74) and/or alcoholic
hepatitis (K70))
 Alcoholism (F10, G31.2, G62.1, G72.1, I42.6, K29.2,
K70)
 Smoking (F17).
 Anatomic or functional asplenia (D57, D73, Q89)
 Primary immunodeficiency (D80-D84)
 HIV infection (B20-B24)
 Chronic renal disease: it included nephrotic
syndrome (N04, N39.1) and severe chronic renal
failure (N18-N19 with glomerular filtration rate ≤
30 ml/min)
 Bone marrow transplantation (Z94)
 Cancer: it included solid organ or haematological
neoplasia (C00 to C97) diagnosed within previous
5 years.
 Immunosupresive therapy: it included long-term
immunosuppressive medication and/or radiotherapy
in the previous 12 months (coded according to
specific SIDIAP codes).
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